Serum Mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis
Purpose: Mesothelin is currently considered the best available serum biomarker of malignant pleural mesothelioma. To examine the diagnostic accuracy and use of serum mesothelin in early diagnosis, we performed an individual patient data (IPD) meta-analysis. Methods: The literature search identified...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 12, 2012
|
| In: |
Journal of clinical oncology
Year: 2012, Jahrgang: 30, Heft: 13, Pages: 1541-1549 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2011.39.6671 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1200/JCO.2011.39.6671 Verlag, Volltext: http://ascopubs.org/doi/10.1200/JCO.2011.39.6671 
|
| Verfasserangaben: | Kevin Hollevoet, Johannes B. Reitsma, Jenette Creaney, Bogdan D. Grigoriu, Bruce W. Robinson, Arnaud Scherpereel, Alfonso Cristaudo, Harvey I. Pass, Kristiaan Nackaerts, José A. Rodríguez Portal, Joachim Schneider, Thomas Muley, Francesca Di Serio, Paul Baas, Marco Tomasetti, Alex J. Rai, and Jan P. van Meerbeeck |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580323715 | ||
| 003 | DE-627 | ||
| 005 | 20220814231306.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180823s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2011.39.6671 |2 doi | |
| 035 | |a (DE-627)1580323715 | ||
| 035 | |a (DE-576)510323715 | ||
| 035 | |a (DE-599)BSZ510323715 | ||
| 035 | |a (OCoLC)1341017400 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hollevoet, Kevin |e VerfasserIn |0 (DE-588)1165250357 |0 (DE-627)1029372586 |0 (DE-576)510323537 |4 aut | |
| 245 | 1 | 0 | |a Serum Mesothelin for diagnosing malignant pleural mesothelioma |b an individual patient data meta-analysis |c Kevin Hollevoet, Johannes B. Reitsma, Jenette Creaney, Bogdan D. Grigoriu, Bruce W. Robinson, Arnaud Scherpereel, Alfonso Cristaudo, Harvey I. Pass, Kristiaan Nackaerts, José A. Rodríguez Portal, Joachim Schneider, Thomas Muley, Francesca Di Serio, Paul Baas, Marco Tomasetti, Alex J. Rai, and Jan P. van Meerbeeck |
| 264 | 1 | |c March 12, 2012 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online March 12, 2012 | ||
| 500 | |a Gesehen am 23.08.2018 | ||
| 520 | |a Purpose: Mesothelin is currently considered the best available serum biomarker of malignant pleural mesothelioma. To examine the diagnostic accuracy and use of serum mesothelin in early diagnosis, we performed an individual patient data (IPD) meta-analysis. Methods: The literature search identified 16 diagnostic studies of serum mesothelin, measured with the Mesomark enzyme-linked immunosorbent assay. IPD of 4,491 individuals were collected, including several control groups and 1,026 patients with malignant pleural mesothelioma. Mesothelin levels were standardized for between-study differences and age, after which the diagnostic accuracy and the factors affecting it were examined with receiver operating characteristic (ROC) regression analysis. Results: At a common diagnostic threshold of 2.00 nmol/L, the sensitivities and specificities of mesothelin in the different studies ranged widely from 19% to 68% and 88% to 100%, respectively. This heterogeneity can be explained by differences in study population, because type of control group, mesothelioma stage, and histologic subtype significantly affected the diagnostic accuracy. The use of mesothelin in early diagnosis was evaluated by differentiating 217 patients with stage I or II epithelioid and biphasic mesothelioma from 1,612 symptomatic or high-risk controls. The resulting area under the ROC curve was 0.77 (95% CI, 0.73 to 0.81). At 95% specificity, mesothelin displayed a sensitivity of 32% (95% CI, 26% to 40%). Conclusion: In patients suspected of having mesothelioma, a positive blood test for mesothelin at a high-specificity threshold is a strong incentive to urge further diagnostic steps. However, the poor sensitivity of mesothelin clearly limits its added value to early diagnosis and emphasizes the need for further biomarker research. | ||
| 700 | 1 | |a Muley, Thomas |e VerfasserIn |0 (DE-588)1056885432 |0 (DE-627)794179169 |0 (DE-576)16759284X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 30(2012), 13, Seite 1541-1549 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Serum Mesothelin for diagnosing malignant pleural mesothelioma an individual patient data meta-analysis |
| 773 | 1 | 8 | |g volume:30 |g year:2012 |g number:13 |g pages:1541-1549 |g extent:9 |a Serum Mesothelin for diagnosing malignant pleural mesothelioma an individual patient data meta-analysis |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.2011.39.6671 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://ascopubs.org/doi/10.1200/JCO.2011.39.6671 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180823 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1056885432 |a Muley, Thomas |m 1056885432:Muley, Thomas |d 910000 |d 950000 |d 950900 |e 910000PM1056885432 |e 950000PM1056885432 |e 950900PM1056885432 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 12 | ||
| 999 | |a KXP-PPN1580323715 |e 3023003017 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Published online March 12, 2012","Gesehen am 23.08.2018"],"recId":"1580323715","type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"subtitle":"an individual patient data meta-analysis","title_sort":"Serum Mesothelin for diagnosing malignant pleural mesothelioma","title":"Serum Mesothelin for diagnosing malignant pleural mesothelioma"}],"person":[{"display":"Hollevoet, Kevin","roleDisplay":"VerfasserIn","role":"aut","given":"Kevin","family":"Hollevoet"},{"given":"Thomas","roleDisplay":"VerfasserIn","role":"aut","display":"Muley, Thomas","family":"Muley"}],"language":["eng"],"name":{"displayForm":["Kevin Hollevoet, Johannes B. Reitsma, Jenette Creaney, Bogdan D. Grigoriu, Bruce W. Robinson, Arnaud Scherpereel, Alfonso Cristaudo, Harvey I. Pass, Kristiaan Nackaerts, José A. Rodríguez Portal, Joachim Schneider, Thomas Muley, Francesca Di Serio, Paul Baas, Marco Tomasetti, Alex J. Rai, and Jan P. van Meerbeeck"]},"id":{"doi":["10.1200/JCO.2011.39.6671"],"eki":["1580323715"]},"physDesc":[{"extent":"9 S."}],"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"March 12, 2012"}],"relHost":[{"origin":[{"dateIssuedDisp":"1983-","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedKey":"1983"}],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Serum Mesothelin for diagnosing malignant pleural mesothelioma an individual patient data meta-analysisJournal of clinical oncology","language":["eng"],"title":[{"subtitle":"JCO : an American Society of Clinical Oncology journal","title_sort":"Journal of clinical oncology","title":"Journal of clinical oncology"}],"id":{"eki":["313116962"],"zdb":["2005181-5"],"issn":["1527-7755"]},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"corporate":[{"display":"American Society of Clinical Oncology","role":"isb","roleDisplay":"Herausgebendes Organ"}],"pubHistory":["1.1983 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"part":{"volume":"30","issue":"13","text":"30(2012), 13, Seite 1541-1549","pages":"1541-1549","year":"2012","extent":"9"},"recId":"313116962"}]} | ||
| SRT | |a HOLLEVOETKSERUMMESOT1220 | ||